We are live on ! Find out more
CC

Casdin Capital Portfolio holdings

AUM $1.32B
1-Year Est. Return 76.62%
This Fund
S&P 500
This Quarter Est. Return
+14.61%
1 Year Est. Return
+76.62%
3 Year Est. Return
+218.92%
5 Year Est. Return
+86.82%
10 Year Est. Return
+4,823.46%
AUM
$823M
AUM Growth
+$108M
Cap. Flow
+$78M
Cap. Flow %
9.48%
Top 10 Hldgs %
55.91%
Holding
41
New
6
Increased
14
Reduced
3
Closed
5

Top Buys

Rank Stock Value
1
BLFS icon
BioLife Solutions
BLFS
+$28.3M
2
NVTA
Invitae Corporation
NVTA
+$27.3M
3
AGIO icon
Agios Pharmaceuticals
AGIO
+$17.3M
4
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
+$14.5M
5
CNST
Constellation Pharmaceuticals, Inc.
CNST
+$12.5M

Top Sells

Rank Stock Value
1
FMI
Foundation Medicine, Inc.
FMI
+$93.6M
2
ZLAB icon
Zai Lab
ZLAB
+$3.14M
3
OSUR icon
OraSure Technologies
OSUR
+$1.88M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$1.77M
5
FATE icon
Fate Therapeutics
FATE
+$591K

Sector Composition

Rank Sector Weight
1 Healthcare 86.5%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LOXO
1
DELISTED
Loxo Oncology, Inc
LOXO
$61.5M 7.47%
360,000
– –
BPMC
2
DELISTED
Blueprint Medicines
BPMC
$58.5M 7.12%
750,000
+115,000
+18% +$7.99M
MYOK
3
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$52.5M 6.38%
805,000
+25,000
+3% +$1.47M
AGIO icon
4
Agios Pharmaceuticals
AGIO
$1.84B
$44.7M 5.43%
579,776
+215,000
+59% +$17.3M
SAGE
5
DELISTED
Sage Therapeutics
SAGE
$44.1M 5.36%
312,000
+62,000
+25% +$9.57M
BLFS icon
6
BioLife Solutions
BLFS
$1.56B
$42.5M 5.17%
2,428,571
+1,428,571
+143% +$28.3M
FATE icon
7
Fate Therapeutics
FATE
$294M
$41.5M 5.05%
2,550,000
-50,000
-2% -$591K
NVTA
8
DELISTED
Invitae Corporation
NVTA
$40.2M 4.88%
+2,400,000
New +$27.3M
BLUE
9
DELISTED
bluebird bio
BLUE
$37.7M 4.58%
19,918
+4,478
+29% +$9.25M
ONCE
10
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$36.8M 4.48%
675,000
+212,000
+46% +$14.5M
CDXS icon
11
Codexis
CDXS
$158M
$34.7M 4.22%
2,025,000
– –
SGMO
12
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$33.9M 4.12%
2,000,000
+600,000
+43% +$9.12M
DNTH icon
13
Dianthus Therapeutics
DNTH
$5.72B
$27M 3.29%
140,676
+13,437
+11% +$2.83M
ILMN icon
14
Illumina
ILMN
$30.2B
$26.2M 3.19%
73,502
– –
GNMK
15
DELISTED
GenMark Diagnostics, Inc
GNMK
$25.7M 3.13%
3,500,000
+100,000
+3% +$734K
BOLD
16
DELISTED
Audentes Therapeutics, Inc
BOLD
$24.7M 3.01%
625,000
+175,000
+39% +$6.52M
ALNY icon
17
Alnylam Pharmaceuticals
ALNY
$29.1B
$23.6M 2.87%
270,000
– –
VYGR icon
18
Voyager Therapeutics
VYGR
$179M
$21.5M 2.61%
1,135,000
– –
GBT
19
DELISTED
Global Blood Therapeutics, Inc.
GBT
$16.7M 2.03%
440,000
-40,000
-8% -$1.77M
EVH icon
20
Evolent Health
EVH
$359M
$15.6M 1.9%
550,000
– –
EDIT icon
21
Editas Medicine
EDIT
$399M
$14.6M 1.78%
460,000
+281,667
+158% +$9.1M
ONC
22
BeOne Medicines Ltd
ONC
$32.3B
$12.1M 1.47%
70,000
– –
GRTS
23
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$10.3M 1.25%
+720,586
New +$10.3M
CRSP icon
24
CRISPR Therapeutics
CRSP
$4.86B
$9.76M 1.19%
220,000
– –
CNST
25
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$8.85M 1.08%
+1,314,743
New +$12.5M
1
2

Similar funds

MDSL
M.D. Sass LLC New York $1.32B AUM 16.01% 1-Year Est. Return
CP
Cumberland Partners Toronto, Ontario, Canada $1.32B AUM 27.83% 1-Year Est. Return
HCM
Hilton Capital Management Garden City, New York $1.32B AUM 15.59% 1-Year Est. Return
MIM
Marco Investment Management Atlanta, Georgia $1.33B AUM 32.43% 1-Year Est. Return
MRL
Mantle Ridge LP New York $1.33B AUM 11.36% 1-Year Est. Return
SWM
SHP Wealth Management Plymouth, Massachusetts $1.33B AUM
MCM
Mill Capital Management Concord, North Carolina $1.31B AUM 17.4% 1-Year Est. Return
B
BloombergSen Toronto, Ontario, Canada $1.31B AUM 8.32% 1-Year Est. Return

Casdin Capital's Q3 2018 Portfolio in Review

As of Q3 2018, Casdin Capital held 41 positions worth $823M, up 15% from $715M the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Casdin Capital deployed $78M of net new capital in Q3 2018, opening 6 new positions and adding to 14 existing holdings. Its largest new stake was Invitae Corporation: 2,400,000 shares worth $40.2M.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, down from 91% a quarter earlier.

On the sell side, the largest reduction was OraSure Technologies, an estimated $1.88M trimmed.

  • Casdin Capital's largest Q3 2018 buy was Invitae Corporation: 2,400,000 shares worth $40.2M.
  • Casdin Capital added most to BioLife Solutions in Q3 2018, an estimated $28.3M increase.
  • Casdin Capital's biggest Q3 2018 reduction was OraSure Technologies, cutting an estimated $1.88M.
  • Casdin Capital fully exited Foundation Medicine, Inc. in Q3 2018, selling an estimated $93.6M.
  • Casdin Capital's ten largest holdings make up 56% of its $823M portfolio in Q3 2018.
  • Casdin Capital opened 6 new positions and closed 5 in Q3 2018.
  • Casdin Capital's portfolio value rose 15% quarter-over-quarter to $823M.

Based on Casdin Capital's 13F filing for Q3 2018, filed 14 Nov 2018.